Legend Biotech Statistics
Total Valuation
Legend Biotech has a market cap or net worth of $6.68 billion. The enterprise value is $6.24 billion.
Important Dates
The last earnings date was Tuesday, May 12, 2026, before market open.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Legend Biotech has 185.74 million shares outstanding. The number of shares has increased by 0.75% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 185.74M |
| Shares Change (YoY) | +0.75% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 52.50% |
| Float | 82.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 45.87 |
| PS Ratio | 5.87 |
| Forward PS | 4.28 |
| PB Ratio | 6.91 |
| P/TBV Ratio | 6.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.13, with a Debt / Equity ratio of 0.40.
| Current Ratio | 2.13 |
| Quick Ratio | 2.01 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.41 |
Financial Efficiency
Return on equity (ROE) is -25.19% and return on invested capital (ROIC) is -27.20%.
| Return on Equity (ROE) | -25.19% |
| Return on Assets (ROA) | -5.24% |
| Return on Invested Capital (ROIC) | -27.20% |
| Return on Capital Employed (ROCE) | -12.38% |
| Weighted Average Cost of Capital (WACC) | 6.08% |
| Revenue Per Employee | $384,148 |
| Profits Per Employee | -$84,351 |
| Employee Count | 2,965 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 26.79 |
Taxes
In the past 12 months, Legend Biotech has paid $13.60 million in taxes.
| Income Tax | 13.60M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +22.72% in the last 52 weeks. The beta is 0.35, so Legend Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | +22.72% |
| 50-Day Moving Average | 24.08 |
| 200-Day Moving Average | 25.82 |
| Relative Strength Index (RSI) | 71.33 |
| Average Volume (20 Days) | 2,945,134 |
Short Selling Information
The latest short interest is 14.43 million, so 19.64% of the outstanding shares have been sold short.
| Short Interest | 14.43M |
| Short Previous Month | 17.00M |
| Short % of Shares Out | 19.64% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.92 |
Income Statement
In the last 12 months, Legend Biotech had revenue of $1.14 billion and -$250.10 million in losses. Loss per share was -$1.38.
| Revenue | 1.14B |
| Gross Profit | 227.80M |
| Operating Income | -134.60M |
| Pretax Income | -236.50M |
| Net Income | -250.10M |
| EBITDA | -125.10M |
| EBIT | -134.60M |
| Loss Per Share | -$1.38 |
Full Income StatementBalance Sheet
The company has $834.60 million in cash and $389.30 million in debt, with a net cash position of $445.30 million or $2.40 per share.
| Cash & Cash Equivalents | 834.60M |
| Total Debt | 389.30M |
| Net Cash | 445.30M |
| Net Cash Per Share | $2.40 |
| Equity (Book Value) | 967.70M |
| Book Value Per Share | 5.21 |
| Working Capital | 573.60M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$81.70 million and capital expenditures -$34.10 million, giving a free cash flow of -$115.80 million.
| Operating Cash Flow | -81.70M |
| Capital Expenditures | -34.10M |
| Depreciation & Amortization | 9.50M |
| Net Borrowing | -4.10M |
| Free Cash Flow | -115.80M |
| FCF Per Share | -$0.62 |
Full Cash Flow StatementMargins
Gross margin is 20.00%, with operating and profit margins of -11.82% and -21.96%.
| Gross Margin | 20.00% |
| Operating Margin | -11.82% |
| Pretax Margin | -20.76% |
| Profit Margin | -21.96% |
| EBITDA Margin | -10.98% |
| EBIT Margin | -11.82% |
| FCF Margin | n/a |
Dividends & Yields
Legend Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.75% |
| Shareholder Yield | -0.75% |
| Earnings Yield | -3.74% |
| FCF Yield | -1.73% |
Analyst Forecast
The average price target for Legend Biotech is $56.39, which is 56.73% higher than the current price. The consensus rating is "Buy".
| Price Target | $56.39 |
| Price Target Difference | 56.73% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 27.86% |
| EPS Growth Forecast (3Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Legend Biotech has an Altman Z-Score of 4.27 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.27 |
| Piotroski F-Score | 3 |
